Bayer's Earnings Came in Below Market Expectations -- Market Talk

Dow Jones11-12

0943 GMT - Bayer's third-quarter Ebitda came in below market expectations, Stifel analysts say in a research note. The German conglomerate posted a quarterly Ebitda of 1.25 billion euros, 10% below consensus estimates. This was due to an accelerated decline in sales of its blood-thinning drug Xarelto, while crop science was as weak as expected, the analysts say. Xarelto declined by 23% on-year but was offset by the growth of prostate-cancer medicine Nubeqa. Bayer's full-year Ebitda guidance in local currencies remains unchanged, but the foreign exchange rate headwind is stronger than expected. Ebitda guidance is now 10.4 billion to 10.7 billion euros, which Stifel estimates saw at 10.0 billion euros and consensus at 10.4 billion euros, the analysts say. Shares trade 11.7% lower at 21.58 euros. (nina.kienle@wsj.com)

(END) Dow Jones Newswires

November 12, 2024 04:43 ET (09:43 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482731177?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-12 17:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482731177","market":"fut","top_or_hot":-1,"title":"Bayer's Earnings Came in Below Market Expectations -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0943 GMT - Bayer's third-quarter Ebitda came in below market expectations, Stifel analysts say in a research note. The German conglomerate posted a quarterly Ebitda of 1.25 billion euros, 10% below consensus estimates. This was due to an accelerated decline in sales of its blood-thinning drug Xarelto, while crop science was as weak as expected, the analysts say. Xarelto declined by 23% on-year but was offset by the growth of prostate-cancer medicine Nubeqa. Bayer's full-year Ebitda guidance in local currencies remains unchanged, but the foreign exchange rate headwind is stronger than expected. Ebitda guidance is now 10.4 billion to 10.7 billion euros, which Stifel estimates saw at 10.0 billion euros and consensus at 10.4 billion euros, the analysts say. Shares trade 11.7% lower at 21.58 euros. (nina.kienle@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 12, 2024 04:43 ET (09:43 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer's Earnings Came in Below Market Expectations -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer's Earnings Came in Below Market Expectations -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 17:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0943 GMT - Bayer's third-quarter Ebitda came in below market expectations, Stifel analysts say in a research note. The German conglomerate posted a quarterly Ebitda of 1.25 billion euros, 10% below ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAYRY","symbol_name":"Bayer A.G.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2482731177","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482731177","pubTimestamp":1731404580,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0943 GMT - Bayer's third-quarter Ebitda came in below market expectations, Stifel analysts say in a research note. The German conglomerate posted a quarterly Ebitda of 1.25 billion euros, 10% below consensus estimates. This was due to an accelerated decline in sales of its blood-thinning drug Xarelto, while crop science was as weak as expected, the analysts say. Xarelto declined by 23% on-year but was offset by the growth of prostate-cancer medicine Nubeqa. Bayer's full-year Ebitda guidance in local currencies remains unchanged, but the foreign exchange rate headwind is stronger than expected. Ebitda guidance is now 10.4 billion to 10.7 billion euros, which Stifel estimates saw at 10.0 billion euros and consensus at 10.4 billion euros, the analysts say. Shares trade 11.7% lower at 21.58 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BAYRY":"Bayer A.G."},"translate_title":"拜耳盈利低于市场预期——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":0.9},"content_text":"0943 GMT - Bayer's third-quarter Ebitda came in below market expectations, Stifel analysts say in a research note. The German conglomerate posted a quarterly Ebitda of 1.25 billion euros, 10% below consensus estimates. This was due to an accelerated decline in sales of its blood-thinning drug Xarelto, while crop science was as weak as expected, the analysts say. Xarelto declined by 23% on-year but was offset by the growth of prostate-cancer medicine Nubeqa. Bayer's full-year Ebitda guidance in local currencies remains unchanged, but the foreign exchange rate headwind is stronger than expected. Ebitda guidance is now 10.4 billion to 10.7 billion euros, which Stifel estimates saw at 10.0 billion euros and consensus at 10.4 billion euros, the analysts say. Shares trade 11.7% lower at 21.58 euros. (nina.kienle@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2024 04:43 ET (09:43 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482731177"}